Establishing Clinical End Points of Respiratory Function in Large Animals for Clinical Translation

Physical Medicine and Rehabilitation Clinics of North America

Volumn 23, Issue 1, 2012, Pages 75-94

  Goddard, Melissa A ^a   Mitchell, Erin L ^b   Smith, Barbara K ^c   Childers, Martin K ^a,d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c WAKE FOREST UNIVERSITY   (United States)

^d WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Respiratory dysfunction; Respiratory impedance plethysmography; X linked myotubular myopathy; XLMTM dog

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; BREATHING MUSCLE; CENTRONUCLEAR MYOPATHY; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE MODEL; DOG; DUCHENNE MUSCULAR DYSTROPHY; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; GENE; HUMAN; IMPEDANCE PLETHYSMOGRAPHY; INSPIRATORY CAPACITY; INVASIVE PROCEDURE; LUNG COMPLICATION; LUNG FUNCTION TEST; MOTOR UNIT POTENTIAL; MTM1 GENE; MUSCLE WEAKNESS; NASAL SNIFF PRESSURE; NEUROMUSCULAR DISEASE; NONHUMAN; PHRENIC NERVE; PNEUMOTACHYGRAPHY; PRIORITY JOURNAL; RESPIRATORY FAILURE; RESPIRATORY TRACT PARAMETERS; REVIEW; TRANSDIAPHRAGMATIC PRESSURE; TRANSLATIONAL RESEARCH; VITAL CAPACITY; X CHROMOSOME LINKED DISORDER;

ANIMALS; DOGS; MODELS, ANIMAL; MYOPATHIES, STRUCTURAL, CONGENITAL; NEUROMUSCULAR DISEASES; RESPIRATION; RESPIRATORY MUSCLES; RESPIRATORY TRACT DISEASES;

EID: 84863418940     PISSN: 10479651     EISSN: 15581381     Source Type: Journal    
DOI: 10.1016/j.pmr.2011.11.017     Document Type: Review

References (75)

1. Mehta S. Neuromuscular disease causing acute respiratory failure. Respir Care 2006, 51(9):1016-1021. [discussion: 1021-3].
2. Shahrizaila N., Kinnear W.J., Wills A.J. Respiratory involvement in inherited primary muscle conditions. JNeurol Neurosurg Psychiatry 2006, 77(10):1108-1115.
3. Racca F., Del Sorbo L., Mongini T., et al. Respiratory management of acute respiratory failure in neuromuscular diseases. Minerva Anestesiol 2010, 76(1):51-62.
4. Howard R.S., Wiles C.M., Hirsch N.P., et al. Respiratory involvement in primary muscle disorders: assessment and management. QJ Med 1993, 86(3):175-189.
5. Mellies U., Lofaso F. Pompe disease: a neuromuscular disease with respiratory muscle involvement. Respir Med 2009, 103(4):477-484.
6. Hahn A., Bach J.R., Delaubier A., et al. Clinical implications of maximal respiratory pressure determinations for individuals with Duchenne muscular dystrophy. Arch Phys Med Rehabil 1997, 78(1):1-6.
7. Bach J.R., O'Brien J., Krotenberg R., et al. Management of end stage respiratory failure in Duchenne muscular dystrophy. Muscle Nerve 1987, 10(2):177-182.
8. Park J.H., Kang S.W., Lee S.C., et al. How respiratory muscle strength correlates with cough capacity in patients with respiratory muscle weakness. Yonsei Med J 2010, 51(3):392-397.
9. Kang S.W., Kang Y.S., Sohn H.S., et al. Respiratory muscle strength and cough capacity in patients with Duchenne muscular dystrophy. Yonsei Med J 2006, 47(2):184-190.
10. Pellegrini N., Laforet P., Orlikowski D., et al. Respiratory insufficiency and limb muscle weakness in adults with Pompe's disease. Eur Respir J 2005, 26(6):1024-1031.
11. Wokke J.H., Escolar D.M., Pestronk A., et al. Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 2008, 38(4):1236-1245.
12. Kaindl A.M., Guenther U.P., Rudnik-Schoneborn S., et al. Spinal muscular atrophy with respiratory distress type 1 (SMARD1). JChild Neurol 2008, 23(2):199-204.
13. Piepers S., van den Berg L.H., Brugman F., et al. Anatural history study of late onset spinal muscular atrophy types 3b and 4. JNeurol 2008, 255(9):1400-1404.
14. Griggs R.C., Donohoe K.M., Utell M.J., et al. Evaluation of pulmonary function in neuromuscular disease. Arch Neurol 1981, 38(1):9-12.
15. Braun N.M., Arora N.S., Rochester D.F. Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies. Thorax 1983, 38(8):616-623.
16. Fromageot C., Lofaso F., Annane D., et al. Supine fall in lung volumes in the assessment of diaphragmatic weakness in neuromuscular disorders. Arch Phys Med Rehabil 2001, 82(1):123-128.
17. Allen J. Pulmonary complications of neuromuscular disease: a respiratory mechanics perspective. Paediatr Respir Rev 2010, 11(1):18-23.
18. Vincken W., Elleker M.G., Cosio M.G. Determinants of respiratory muscle weakness in stable chronic neuromuscular disorders. Am J Med 1987, 82(1):53-58.
19. Black L.F., Hyatt R.E. Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis 1969, 99(5):696-702.
20. Wilson S.H., Cooke N.T., Edwards R.H., et al. Predicted normal values for maximal respiratory pressures in Caucasian adults and children. Thorax 1984, 39(7):535-538.
21. Harikumar G., Moxham J., Greenough A., et al. Measurement of maximal inspiratory pressure in ventilated children. Pediatr Pulmonol 2008, 43(11):1085-1091.
22. Truwit J.D., Marini J.J. Validation of a technique to assess maximal inspiratory pressure in poorly cooperative patients. Chest 1992, 102(4):1216-1219.
23. ATS/ERS ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med 2002, 166(4):518-624.
24. Hart N., Polkey M.I., Sharshar T., et al. Limitations of sniff nasal pressure in patients with severe neuromuscular weakness. JNeurol Neurosurg Psychiatry 2003, 74(12):1685-1687.
25. Nava S., Ambrosino N., Crotti P., et al. Recruitment of some respiratory muscles during three maximal inspiratory manoeuvres. Thorax 1993, 48(7):702-707.
26. Terzi N., Orlikowski D., Fermanian C., et al. Measuring inspiratory muscle strength in neuromuscular disease: one test or two?. Eur Respir J 2008, 31(1):93-98.
27. Steier J., Kaul S., Seymour J., et al. The value of multiple tests of respiratory muscle strength. Thorax 2007, 62(11):975-980.
28. de Torres J.P., Talamo C., Aguirre-Jaime A., et al. Electromyographic validation of the mouth pressure-time index: a noninvasive assessment of inspiratory muscle load. Respir Med 2003, 97(9):1006-1013.
29. Beck J., Weinberg J., Hamnegard C.H., et al. Diaphragmatic function in advanced Duchenne muscular dystrophy. Neuromuscul Disord 2006, 16(3):161-167.
30. Bolton C.F. Phrenic nerve conduction studies: technical aspects and normative data. Muscle Nerve 2008, 38(6):1658-1659.
31. Perrin C., Unterborn J.N., Ambrosio C.D., et al. Pulmonary complications of chronic neuromuscular diseases and their management. Muscle Nerve 2004, 29(1):5-27.
32. Bellemare F., Grassino A. Effect of pressure and timing of contraction on human diaphragm fatigue. JAppl Physiol 1982, 53(5):1190-1195.
33. Misuri G., Lanini B., Gigliotti F., et al. Mechanism of CO(2) retention in patients with neuromuscular disease. Chest 2000, 117(2):447-453.
34. Nava S., Rubini F., Zanotti E., et al. The tension-time index of the diaphragm revisited in quadriplegic patients with diaphragm pacing. Am J Respir Crit Care Med 1996, 153(4 Pt 1):1322-1327.
35. Chaudri M.B., Liu C., Hubbard R., et al. Relationship between supramaximal flow during cough and mortality in motor neurone disease. Eur Respir J 2002, 19(3):434-438.
36. Polkey M.I., Lyall R.A., Green M., et al. Expiratory muscle function in amyotrophic lateral sclerosis. Am J Respir Crit Care Med 1998, 158(3):734-741.
37. Man W.D., Kyroussis D., Fleming T.A., et al. Cough gastric pressure and maximum expiratory mouth pressure in humans. Am J Respir Crit Care Med 2003, 168(6):714-717.
38. Noguchi S., Fujita M., Murayama K., et al. Gene expression analyses in X-linked myotubular myopathy. Neurology 2005, 65(5):732-737.
39. Jungbluth H., Wallgren-Pettersson C., Laporte J. Centronuclear (myotubular) myopathy. Orphanet J Rare Dis 2008, 3:26.
40. Laporte J., Biancalana V., Tanner S.M., et al. MTM1 mutations in X-linked myotubular myopathy. Hum Mutat 2000, 15(5):393-409.
41. Mruk D.D., Cheng C.Y. The myotubularin family of lipid phosphatases in disease and in spermatogenesis. Biochem J 2011, 433(2):253-262.
42. Herman G.E., Finegold M., Zhao W., et al. Medical complications in long-term survivors with X-linked myotubular myopathy. JPediatr 1999, 134(2):206-214.
43. Spiro A.J., Shy G.M., Gonatas N.K. Myotubular myopathy. Persistence of fetal muscle in an adolescent boy. Arch Neurol 1966, 14(1):1-14.
44. Fardeau M. Congenital myopathies. Skeletal muscle pathology 1992, 1177. Churchill Livingstone, Edinburgh (UK); New York. F.L. Mastaglia, L.W.O. Detchant (Eds.).
45. Beggs A.H., Böhm J., Snead E., et al. MTM1 mutation associated with X-linked myotubular myopathy in Labrador Retrievers. Proc Natl Acad Sci USA 2010, 107(33):14697-14702.
46. Murphy D.J. Comprehensive non-clinical respiratory evaluation of promising new drugs. Toxicol Appl Pharmacol 2005, 207(Suppl 2):414-424.
47. Cummings J.F. Nervous system. Spontaneous animal models of human disease. vol. 2 1997, 109. Academic Press, New York. E.J. Andrews, B.C. Ward, N.H. Altman (Eds.).
48. Dowling J.J., Vreede A.P., Low S.E., et al. Loss of myotubularin function results in T-tubule disorganization in zebrafish and human myotubular myopathy. PLoS Genet 2009, 5(2):e1000372.
49. Buj-Bello A., Laugel V., Messaddeq N., et al. The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice. Proc Natl Acad Sci USA 2002, 99(23):15060-15065.
50. Arruda V.R., Stedman H.H., Nichols T.C., et al. Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 2005, 105(9):3458-3464.
51. Zhang G., Budker V., Wolff J.A. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999, 10(10):1735-1737.
52. Jungbluth H., Wallgren-Pettersson C., Laporte J.F., et al. 164th ENMC International workshop: 6th workshop on centronuclear (myotubular) myopathies, 16-18th January 2009, Naarden, The Netherlands. Neuromuscul Disord 2009, 19(10):721-729.
53. Shimatsu Y., Katagiri K., Furuta T., et al. Canine X-linked muscular dystrophy in Japan (CXMDJ). Exp Anim 2003, 52(2):93-97.
54. Hrapkiewicz K., Medina L. Clinical laboratory animal medicine 2007, Blackwell Publishing, Ames. 3rd edition.
55. Cunningham J. Textbook of veterinary physiology 1997, W.B. Saunders Company, Philadelphia. 2nd edition.
56. Evans H.E. Miller's anatomy of the dog 1993, W.B. Saunders Company, Philadelphia. 3rd edition.
57. Johnston S., Kustiritz M., Olson P. Canine and feline theriogenology 2001, W.B. Saunders Company, St. Louis.
58. Feldman E.C., Nelson R.W. Canine and feline endocrinology and reproduction 2004, W.B. Saunders, St. Louis. 3rd edition.
59. Cooper B.J., Winand N.J., Stedman H., et al. The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature 1988, 334(6178):154-156.
60. Paoloni M., Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008, 8(2):147-156.
61. Cosford K.L., Taylor S.M., Thompson L., et al. Apossible new inherited myopathy in a young Labrador retriever. Can Vet J 2008, 49(4):393-397.
62. Shelton G.D. Neuromuscular disorders affecting young dogs and cats. Vet Neurol Neurosurg J 1999, 1(1):1.
63. Valentine B.A., Cooper B.J., de Lahunta A., et al. Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. JNeurol Sci 1988, 88(1-3):69-81.
64. Kornegay J.N., Tuler S.M., Miller D.M., et al. Muscular dystrophy in a litter of golden retriever dogs. Muscle Nerve 1988, 11(10):1056-1064.
65. Kornegay J.N., Bogan J.R., Bogan D.J., et al. Golden retriever muscular dystrophy (GRMD): Developing and maintaining a colony and physiological functional measurements. Methods Mol Biol 2011, 709:105-123.
66. Shimatsu Y., Yoshimura M., Yuasa K., et al. Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ. Acta Myol 2005, 24(2):145-154.
67. Jaber S., Petrof B.J., Jung B., et al. Rapidly progressive diaphragmatic weakness and injury during mechanical ventilation in humans. Am J Respir Crit Care Med 2011, 183(3):364-371.
68. Kearney K., Metea M., Gleason T., et al. Evaluation of respiratory function in freely moving Beagle dogs using implanted impedance technology. JPharmacol Toxicol Methods 2010, 62(2):119-126.
69. Murphy D.J., Renninger J.P., Schramek D. Respiratory inductive plethysmography as a method for measuring ventilatory parameters in conscious, non-restrained dogs. JPharmacol Toxicol Methods 2010, 62(1):47-53.
70. Marini J.J., Rodriguez R.M., Lamb V. Bedside estimation of the inspiratory work of breathing during mechanical ventilation. Chest 1986, 89(1):56-63.
71. Laghi F., Cattapan S.E., Jubran A., et al. Is weaning failure caused by low-frequency fatigue of the diaphragm?. Am J Respir Crit Care Med 2003, 167(2):120-127.
72. Hubmayr R.D., Sprung J., Nelson S. Determinants of transdiaphragmatic pressure in dogs. JAppl Physiol 1990, 69(6):2050-2056.
73. Papich MG. Saunders. In: Winkel A, acquisitions editor, Slaten, M, development editor. Handbook of veterinary drugs. St Louis (MO): W.B. Saunders; 2007. p. 22.
74. Muir W., Hubbell J. Handbook of veterinary anesthesia 2000, Mosby, St Louis. 3rd edition.
75. Yost C.S. Anew look at the respiratory stimulant doxapram. CNS Drug Rev 2006, 12(3-4):236-249.